Danaher Stock Analysis: What the Latest DHR Results Mean for Investors

Danaher reported third-quarter 2026 results before the US open on Wednesday 21 October, and the number that matters is not the headline one. Adjusted earnings per share came in at USD 2.11 against a consensus of USD 1.92 — a beat of close to 10%, and up 11.5% year on year — on revenue of approximately USD 6.6bn, up 8.5%. But core revenue growth was reported at 3.0%, while core revenue excluding respiratory testing grew 5.5%. The 250 basis points between those two figures is the entire Danaher story at the moment. The company also raised full-year 2026 adjusted EPS guidance to USD 8.57 to USD 8.62.

For a Danaher stock analysis, the useful framing is that this is a company with two businesses inside one core growth number: a recovering bioprocessing and life-sciences franchise growing in the mid single digits, and a respiratory-testing line in structural decline that is dragging the reported figure down by roughly a quarter of its value. The guidance raise and the near-10% EPS beat say the recovering half is working. The 3.0% headline says the drag is still material. What changes the arithmetic from here is that Danaher guided the respiratory headwind down to about 150 basis points for the fourth quarter, from the roughly 250 basis points it cost in the third — so the gap between the two growth numbers is set to narrow mechanically, without the underlying business having to accelerate at all.

What the results actually showed

On the statutory numbers, GAAP net earnings were USD 1.2bn, or USD 1.71 per diluted common share, up 34.5% year on year. Against revenue of approximately USD 6.6bn, that is a net margin of roughly 18% — and net earnings growing 34.5% on revenue growing 8.5% is substantial operating leverage, considerably faster than the 11.5% growth in the adjusted EPS figure.

A note on bases, because this release is one where mixing them produces nonsense. The USD 2.11 for the quarter and the USD 8.57 to USD 8.62 full-year range are adjusted, non-GAAP figures. The USD 1.71 per diluted share is GAAP. Core revenue growth of 3.0% and core growth excluding respiratory of 5.5% are both non-GAAP measures. These are not alternative estimates of the same quantity and the gaps between them are not margin commentary.

On revenue, the beat was narrower than the EPS beat and arguably was not a beat at all. Consensus sat at approximately USD 6.55bn and reported revenue was approximately USD 6.55bn to USD 6.6bn depending on the source — one outlet described revenue as USD 10m short of consensus, another as ahead of it, and Zacks-based coverage described it as simply in line. The defensible statement is that Danaher beat on earnings and met on revenue. The quarter was a margin and execution beat, not a demand surprise.

Core growth excluding respiratory at 5.5% was described across coverage as an acceleration on the prior quarter, and the company's fourth-quarter guidance is for that measure to grow 4.0% to 5.0% year on year with respiratory a roughly 150 basis point headwind.

Why the market did not simply buy the beat

A near-10% EPS beat with a guidance raise would normally be read straightforwardly. It was not, and the reporting of the 21 October session is genuinely conflicting: one account described the shares falling in premarket trading after the result, while another from the same publisher described them rising in premarket trade on the beat. Because the direction cannot be corroborated, no move figure is quoted here.

The reason for the hesitation is visible in the guidance rather than the quarter. Danaher told the market to expect core growth excluding respiratory of 4.0% to 5.0% in the fourth quarter. That is below the 5.5% just delivered. For investors who had been treating the bioprocessing recovery as an accelerating story — destocking ending, order books rebuilding, growth stepping up through the year — a guided deceleration in the cleanest growth measure the company publishes is the opposite of confirmation. It reframes the recovery as a stabilisation at mid-single-digit rates rather than a return to the high-single-digit or low-double-digit growth the franchise delivered before the inventory correction.

The second factor is that the EPS beat was not primarily a revenue event. When a beat of that size arrives on in-line revenue, it came from margin and below-the-line items, and the market discounts margin beats more heavily than demand beats because they are harder to repeat.

The Openbook read

Growth is the most interesting score here because the honest answer is that it depends which measure you accept, and the right approach is to score both. On reported core revenue growth of 3.0%, Danaher is a low-growth business. On core growth excluding respiratory of 5.5%, it is a mid-single-digit grower consistent with the life-sciences tools sector. The reason the second measure deserves the weight is that the respiratory decline is a known, finite and shrinking quantity — it halves as a drag in the fourth quarter, to roughly 150 basis points — rather than an open-ended deterioration. The reason it cannot be given all the weight is that an adjustment the company controls the definition of should never be the only number in a growth score. We score growth off the ex-respiratory line while holding the headline as the floor.

Profitability is the clear strength and justifies the guidance raise. Roughly 18% GAAP net margin, net earnings up 34.5% on revenue up 8.5%, and adjusted EPS up 11.5% all point the same way. A company able to raise its full-year adjusted EPS range in the third quarter is a company whose cost base is behaving as planned while its revenue mix improves. Of the five factors, this is the one the quarter unambiguously improved.

Solvency is not directly tested by this release and does not change. The relevant observation is that the guidance raise is funded by delivered earnings rather than by an assumption about the fourth quarter — the first three quarters did the work.

Momentum should be treated as unresolved. The session reaction cannot be established from available reporting, and a guidance raise met with an uncertain tape is not a momentum signal in either direction.

Reward/Risk is the factor that the two growth measures ultimately resolve into, and it is more favourable than the 3.0% headline implies, for a specific and unglamorous reason: the thing suppressing the headline is scheduled to stop. Respiratory testing has been a roughly 250 basis point drag and is guided to about 150 basis points next quarter. As that comp washes through, reported core growth converges upward towards the ex-respiratory rate without management having to deliver anything new. The risk on the other side is equally concrete — the 4.0% to 5.0% fourth-quarter guide for core ex-respiratory growth sets the base rate for the recovering business in the mid single digits, and if that is where bioprocessing settles rather than a waypoint on the way back up, then the convergence delivers a mid-single-digit grower rather than the franchise the sector used to be. Full factor scores are on the Danaher equity page.

The read-across

Two distinct signals here travel to two different peer groups, and conflating them is the common error.

The bioprocessing and life-sciences read is the one that matters for Thermo Fisher Scientific, Agilent Technologies and Revvity. Core growth excluding respiratory at 5.5%, accelerating, with a 4.0% to 5.0% fourth-quarter guide, is a statement that the post-pandemic destocking cycle in bioprocessing consumables has substantially worked through — but that the sector is normalising to mid-single-digit growth rather than snapping back to its prior trend rate. Peers reporting over the coming weeks will be measured against that benchmark, and the ones guiding materially above it will need to explain why.

The respiratory-testing read belongs to the diagnostics names rather than the tools names. Danaher's respiratory line is in managed decline against elevated prior-year comparisons, and that normalisation is an industry condition, not a Danaher-specific one. Any diagnostics business whose recent reported growth has been supported by respiratory volumes faces the same mechanical headwind and the same eventual relief as the comparison base resets. Separating the two effects is exactly the kind of test our stock screener is built for: screening the group on headline revenue growth alone will rank these businesses in close to the wrong order.

What to watch next

• Fourth-quarter and full-year 2026 results, expected late January or February 2027. The single number to check is core revenue growth excluding respiratory against the guided 4.0% to 5.0%. Coming in at the top of that range or above it turns the stabilisation reading back into an acceleration reading.
• The respiratory headwind itself. Guided at roughly 150 basis points for the fourth quarter, from roughly 250 in the third. If it comes in lighter than 150bp, reported core growth converges towards the ex-respiratory rate faster than currently modelled.
• Full-year adjusted EPS against USD 8.57 to USD 8.62. A narrow range raised in the third quarter leaves little room, so delivery inside it is the base case and any miss would be read as a margin problem rather than a demand one.
• 2027 initial guidance. This is where Danaher has to state whether mid-single-digit core growth is the new baseline for the recovered business or a step on the way to something faster. It is the most consequential disclosure still to come.

Danaher delivered the earnings and raised the guidance. What it did not deliver is evidence that the recovering half of the business is still speeding up — and on the fourth-quarter guide, it told the market not to expect that for now.